CoChat
Sign Up
Cited by 192Sepsis Diagnosis and TreatmentAcute Kidney Injury ResearchInflammation biomarkers and pathways

Cytokine removal in human septic shock: Where are we and where are we going?

Open access
Honore, Patrick M., Hoste, Eric, Molnár, Zsolt, Jacobs, Rita, Joannes-Boyau, Olivier, Malbrain, Manu L. N.G., Forni, Lui G.·2019·Annals of Intensive Care
DOI 10.1186/s13613-019-0530-yPMC PMC6517449
Open this paper in CoChat — free accountOpen PDF

Abstract

Although improving, the mortality from septic shock still remains high despite increased international awareness. As a consequence, much effort has focused on alternative treatment strategies in an effort to improve outcomes. The application of blood purification therapies to improve immune homeostasis has been suggested as one such method, but these approaches, such as high-volume continuous haemofiltration or cytokine and/or endotoxin removal, have enjoyed little success to date. More recently, the use of sorbent technologies has attracted much attention. These adsorbers are highly effective at removing inflammatory mediators, in particular, cytokines, from the bloodstream. This narrative review is the executive summary of meetings held throughout the 6th International Fluid Academy Days in Antwerp, Belgium (Nov 23-25, 2017), focusing on the current understanding regarding the use of such adsorbers in humans with septic shock. We followed a modified Delphi approach involving a combination of evidence appraisal together with expert opinion in order to achieve recommendations for practice and, importantly, future research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13613-019-0530-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cellular and subsequent organ damage results from complex and interacting assaults involving endothelial activation, coagulopathy, disturbances in microcirculation, impaired mitochondrial function, enhanced apoptosis, increased gut permeability, and altered glucose and protein metabolism.

    “Cellular and subsequent organ damage results from complex and interacting assaults involving endothelial activation, coagulopathy, disturbances in microcirculation, impaired mitochondrial function, enhanced apoptosis, increased gut permeability, and altered glucose and protein metabolism [5].”

    From Nutrition in Sepsis: A Bench-to-Bedside Review. (2020) · cites this paper as [5]

    In the Introduction, “The place for blood purification” says DAMPs can induce cellular damage and apoptosis; “Cytokine storm and capillary leak” links vascular leakage and oedema to organ dysfunction or failure. Our copy does not substantiate the full list of mechanisms, particularly coagulopathy, microcirculatory and mitochondrial dysfunction, gut permeability, or altered glucose and protein metabolism. The indexed passages provide no page numbers. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 86

  1. [1]Rhee C Dantes R Epstein L CDC prevention epicenter program Incidence and trends of sepsis in US Hospitals using clinical vs claims data, 2009–2014 JAMA 2017 318 1241 1249 10.1001/jama.2017.13836 28903154 PMC5710396 · DOI · Paper page
  2. [2]Rimmer E Houston BL Kumar A The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis Crit Care 2014 18 699 10.1186/s13054-014-0699-2 25527094 PMC4318234 · DOI
  3. [3]Stoller J Halpin L Weis M Epidemiology of severe sepsis: 2008–2012 J Crit Care 2016 31 1 58 62 10.1016/j.jcrc.2015.09.034 26601855 · DOI
  4. [4]Machado FR Cavalcanti AB Bozza FA SPREAD Investigators; Latin American Sepsis Institute Network The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study Lancet Infect Dis 2017 17 1180 1189 10.1016/S1473-3099(17)30322-5 28826588 · DOI · Paper page
  5. [5]Shankar-Hari M Ambler M Mahalingasivam V Jones A Rowan K Rubenfeld GD Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies Crit Care 2016 20 101 10.1186/s13054-016-1276-7 27075205 PMC4831092 · DOI
  6. [6]Harrison AM Gajic O Pickering BW Herasevich V Development and implementation of sepsis alert systems Clin Chest Med 2016 37 219 229 10.1016/j.ccm.2016.01.004 27229639 PMC4884325 · DOI · Paper page
  7. [7]Gaieski DF Edwards JM Kallan MJ Carr BG Benchmarking the incidence and mortality of severe sepsis in the United States Crit Care Med 2013 41 1167 1174 10.1097/CCM.0b013e31827c09f8 23442987 · DOI
  8. [8]Kaukonen KM Bailey M Suzuki S Pilcher D Bellomo R Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012 JAMA 2014 311 1308 1316 10.1001/jama.2014.2637 24638143 · DOI
  9. [9]Angus DC van der Poll T Severe sepsis and septic shock N Engl J Med 2013 369 840 851 10.1056/NEJMra1208623 23984731 · DOI
  10. [11]Iskander KN Osuchowski MF Stearns-Kurosawa DJ Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding Physiol Rev 2013 93 1247 1288 10.1152/physrev.00037.2012 23899564 PMC3962548 · DOI
  11. [12]Dreiher J Almog Y Sprung CL SEPSIS-ISR Group Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis Crit Care Med 2012 40 3 855 860 10.1097/CCM.0b013e318236f7b8 22020241 · DOI
  12. [13]Kadri SS Rhee C Strich JR Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data Chest 2017 151 278 285 10.1016/j.chest.2016.07.010 27452768 PMC5310115 · DOI
  13. [14]Stevenson EK Rubenstein AR Radin GT Wiener RS Walkey A Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis Crit Care Med 2014 42 625 631 10.1097/CCM.0000000000000026 24201173 PMC4313930 · DOI
  14. [15]Iwashyna TJ Cooke CR Wunsch H Kahn JM Population burden of long-term survivorship after severe sepsis in older Americans J Am Geriatr Soc 2012 60 1070 1077 10.1111/j.1532-5415.2012.03989.x 22642542 PMC3374893 · DOI
  15. [16]Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011: statistical brief #160 Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD); 2006. 24199255
  16. [17]Dellinger RP Levy MM Rhodes A Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012 Intensive Care Med 2013 39 165 228 10.1007/s00134-012-2769-8 23361625 PMC7095153 · DOI
  17. [18]Zhou F Peng Z Murugan R Kellum JA Blood purification and mortality in sepsis: a meta-analysis of randomized trials Crit Care Med 2013 41 2209 2220 10.1097/CCM.0b013e31828cf412 23860248 PMC3758418 · DOI · Paper page
  18. [19]Callard R George AJ Stark J Cytokines, chaos, and complexity Immunity 1999 11 507 513 10.1016/S1074-7613(00)80125-9 10591175 · DOI
  19. [20]Singer M Deutschman CS Seymour CW The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA 2016 315 8 801 810 10.1001/jama.2016.0287 26903338 PMC4968574 · DOI · Paper page
  20. [21]Ronco C Tetta C Mariano F Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis Artif Organs 2003 27 9 792 801 10.1046/j.1525-1594.2003.07289.x 12940901 · DOI
  21. [22]van der Poll T van de Veerdonk FL Scicluna BP Netea MG The immunopathology of sepsis and potential therapeutic targets Nat Rev Immunol 2017 17 7 407 420 10.1038/nri.2017.36 28436424 · DOI · Paper page
  22. [23]Honoré PM Matson JR Extracorporeal removal for sepsis: acting at the tissue level–the beginning of a new era for this treatment modality in septic shock Crit Care Med 2004 32 3 896 897 10.1097/01.CCM.0000115262.31804.46 15090989 · DOI
  23. [24]Di Carlo JV Alexander SR Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis Int J Artif Organs 2005 28 777 786 10.1177/039139880502800803 16211527 · DOI
  24. [25]Peng ZY Bishop JV Wen XY Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model Crit Care 2014 18 R141 10.1186/cc13969 24992991 PMC4227131 · DOI
  25. [26]Lukaszewicz AC Payen D Purification methods: a way to treat severe acute inflammation related to sepsis? Crit Care 2013 17 159 10.1186/cc12757 23805829 PMC3706942 · DOI
  26. [27]Cole L Bellomo R Journois D Davenport P Baldwin I Tipping P High-volume haemofiltration in human septic shock Intensive Care Med 2001 27 978 986 10.1007/s001340100963 11497156 · DOI
  27. [28]Honore PM Jamez J Wauthier M Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock Crit Care Med 2000 28 3581 3587 10.1097/00003246-200011000-00001 11098957 · DOI
  28. [29]Joannes-Boyau O Honore PM Perez P High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial Intensive Care Med 2013 39 1535 1546 10.1007/s00134-013-2967-z 23740278 · DOI
  29. [30]Clark E Molnar AO Joannes-Boyau O Honore PM Sikora L Bagshaw SM High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis Crit Care 2014 18 R7 10.1186/cc13184 24398168 PMC4057068 · DOI
  30. [31]Cavaillon JM Munoz C Fitting C Misset B Carlet J Circulating cytokines: the tip of the iceberg? Circ Shock 1992 38 2 145 152 1423923
  31. [32]Sun S Sursal T Adibnia Y Zhao C Zheng Y Li H LE Otterbein Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways PLoS ONE 2013 8 3 e59989 10.1371/journal.pone.0059989 23527291 PMC3603956 · DOI
  32. [33]Vincent JL Laterre PF Cohen J A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection Shock 2005 23 400 405 10.1097/01.shk.0000159930.87737.8a 15834304 · DOI
  33. [34]Cruz DN Antonelli M Fumagalli R Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial JAMA 2009 301 2445 2452 10.1001/jama.2009.856 19531784 · DOI
  34. [35]Payen DM Guilhot J Launey Y ABDOMIX Group Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial Intensive Care Med 2015 41 975 984 10.1007/s00134-015-3751-z 25862039 PMC4477725 · DOI
  35. [36]Coudroy R Payen D Launey Y ABDOMIX group Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis Shock 2017 47 93 10.1097/SHK.0000000000000725 27984535 · DOI
  36. [38]Iba T Fowler L Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial J Intensive Care 2017 5 40 10.1186/s40560-017-0236-x 28690852 PMC5496228 · DOI
  37. [39]Chang T Tu Y-K Lee C-T Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis Crit Care Med 2017 45 e858 e864 10.1097/CCM.0000000000002362 28445237 PMC5515642 · DOI
  38. [40]Payen D Haemoperfusion with polymyxin B membrane: recent results for an old debate! Anaesth Crit Care Pain Med 2019 38 1 3 4 10.1016/j.accpm.2018.12.010 30635098 · DOI
  39. [41]Pickkers P Russell JA Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy? Intensive Care Med 2019 45 2 282 283 10.1007/s00134-018-5481-5 30511248 · DOI
  40. [42]Duchesne JC Kaplan LJ Balogh ZJ Malbrain MNLG Role of permissive hypotension, hypertonic resuscitation and the global increased permeability syndrome in patients with severe haemorrhage: adjuncts to damage control resuscitation to prevent intra-abdominal hypertension Anaesthesiol Intensive Ther 2015 47 143 155 10.5603/AIT.a2014.0052 25293626 · DOI
  41. [44]Gruda MC Ruggeberg KG O’Sullivan P Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads PLoS ONE 2018 13 e0191676 10.1371/journal.pone.0191676 29370247 PMC5784931 · DOI
  42. [45]Malbrain ML Marik PE Witters I Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice Anaesthesiol Intensive Ther 2014 46 5 361 380 10.5603/ait.2014.0060 25432556 · DOI
  43. [46]Kobe Y Oda S Matsuda K Nakamura M Hirasawa H Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study Blood Purif 2007 25 446 453 10.1159/000111568 18037813 PMC2813796 · DOI
  44. [47]Pfortmueller CA Meisel C Fux M Schefold JC Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers Intensive Care Med Exp 2017 5 49 10.1186/s40635-017-0163-0 29063386 PMC5653680 · DOI
  45. [48]Hotchkiss RS Monneret G Payen D Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Lancet Infect Dis 2013 13 260 268 10.1016/S1473-3099(13)70001-X 23427891 PMC3798159 · DOI
  46. [49]Monneret G Venet F Pachot A Lepape A Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony Mol Med 2008 14 64 78 10.2119/2007-00102.Monneret 18026569 PMC2078557 · DOI
  47. [50]Boomer JS To K Chang KC Immunosuppression in patients who die of sepsis and multiple organ failure JAMA 2011 306 2594 2605 10.1001/jama.2011.1829 22187279 PMC3361243 · DOI
  48. [51]Schefold JC Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure Intensive Care Med 2010 36 1810 1812 10.1007/s00134-010-1965-7 20652681 · DOI
  49. [52]Leentjens J Kox M Koch RM Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study Am J Respir Crit Care Med 2012 186 838 845 10.1164/rccm.201204-0645OC 22822024 · DOI
  50. [53]Drewry AM Ablordeppey EA Murray ET Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study Crit Care 2016 20 334 10.1186/s13054-016-1505-0 27760554 PMC5072304 · DOI
  51. [54]Quinto BM Iizuka IJ Monte JC TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment Cytokine 2015 71 2 255 260 10.1016/j.cyto.2014.10.024 25461406 · DOI
  52. [55]Van Snick J Interleukin-6: an overview Annu Rev Immunol 1990 8 253 278 10.1146/annurev.iy.08.040190.001345 2188664 · DOI · Paper page
  53. [56]Venet F Lukaszewicz AC Payen D Hotchkiss R Monneret G Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies Curr Opin Immunol 2013 25 477 483 10.1016/j.coi.2013.05.006 23725873 PMC3931134 · DOI
  54. [57]Monneret G Finck ME Venet F The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration Immunol Lett 2004 95 193 198 10.1016/j.imlet.2004.07.009 15388260 · DOI
  55. [58]Frencken JF van Vught LA Peelen LM An unbalanced inflammatory cytokine response is not associated with mortality following sepsis: a prospective cohort study Crit Care Med 2017 45 e493 e499 10.1097/CCM.0000000000002292 28257334 · DOI
  56. [59]Kellum JA Kong L Fink MP Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study Arch Intern Med 2007 167 1655 1663 10.1001/archinte.167.15.1655 17698689 PMC4495652 · DOI
  57. [60]De Vriese AS Colardyn FA Philippe JJ Vanholder RC De Sutter JH Lameire NH Cytokine removal during continuous hemofiltration in septic patients J Am Soc Nephrol 1999 10 846 853 10203370
  58. [61]Kellum JA Song M Venkataraman R Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia Crit Care Med 2004 32 801 805 10.1097/01.CCM.0000114997.39857.69 15090965 · DOI
  59. [62]Namas RA Namas R Lagoa C Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: insights from in vivo and in silico studies Mol Med 2012 18 1366 1374 10.2119/molmed.2012.00106 22751621 PMC3533640 · DOI
  60. [63]Peng ZY Carter MJ Kellum JA Effects of hemoadsorption on cytokine removal and short-term survival in septic rats Crit Care Med 2008 36 1573 1577 10.1097/CCM.0b013e318170b9a7 18434884 PMC3547590 · DOI
  61. [64]Peng ZY Wang HZ Carter MJ Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis Kidney Int 2012 81 363 369 10.1038/ki.2011.320 21918497 PMC3269547 · DOI
  62. [65]Kellum JA Venkataraman R Powner D Elder M Hergenroeder G Carter M Feasibility study of cytokine removal by hemoadsorption in brain-dead humans Crit Care Med 2008 36 268 272 10.1097/01.CCM.0000291646.34815.BB 18090355 · DOI
  63. [66]Poli EC Alberio L Bauer-Doerries A Marcucci C Roumy A Kirsch M Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial Crit Care 2019 23 1 108 10.1186/s13054-019-2399-4 30944029 PMC6448322 · DOI
  64. [67]Sathe PSP Kumar S Choudhary S Clinical experience of using a novel extracorporeal cytokine adsorption column for treatment of septic shock with multiorgan failure Crit Care (London, England) 2015 19 Suppl 1 P130 10.1186/cc14210 · DOI
  65. [68]Honoré Patrick M Matson James R Critical Care 2002 6 5 394 10.1186/cc1826 12398774 PMC137327 · DOI
  66. [69]Matson J Zydney A Honoré PM Blood filtration: new opportunities and the implications of systems biology Crit Care Resusc 2004 6 209 217 16556124
  67. [70]DA Laddomada T Balicco B Case series of patients with severe sepsis and septic shock treated with a new extracorporeal sorbent Crit care (London, England) 2016 20 P193 10.1186/s13054-016-1372-8 · DOI
  68. [71]Kogelmann K Jarczak D Scheller M Druner M Hemoadsorption by CytoSorb in septic patients: a case series Crit Care 2017 21 74 10.1186/s13054-017-1662-9 28343448 PMC5366999 · DOI
  69. [72]Friesecke S Stecher SS Gross S Felix SB Nierhaus A Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study J Artif Organs 2017 20 252 259 10.1007/s10047-017-0967-4 28589286 · DOI
  70. [74]Schadler D Pausch C Heise D The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial PLoS ONE 2017 12 e0187015 10.1371/journal.pone.0187015 29084247 PMC5662220 · DOI
  71. [75]Friesecke S Träger K Schittek GA International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results Med Klin Intensivmed Notfmed 2017 10.1007/s00063-017-0342-5 28871441 · DOI
  72. [76]Bernardi MH Rinoesl H Dragosits K Effect of hemoadsorption during cardiopulmonary bypass surgery—a blinded, randomized, controlled pilot study using a novel adsorbent Crit Care 2016 20 96 10.1186/s13054-016-1270-0 27059056 PMC4826492 · DOI
  73. [77]Nemeth E Kovacs E Racz K Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation—an observational study Clin Transpl 2018 10.1111/ctr.13211 29377282 · DOI
  74. [78]Öveges N Hawchar F László I Early cytokine adsorption in septic shock (ACESS-trial): results of a proof concept, pilot study Crit Care 2018 22 Suppl 1 82 30448517
  75. [79]Hawchar F Lazlo I Oveges N Trasy D Molnar Z Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study J Crit Care 2018 10.1016/j.jcrc.2018.11.003 30448517 · DOI
  76. [80]Bellani G Laffey JG Pham T LUNG SAFE Investigators; ESICM Trials Group Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries JAMA 2016 315 8 788 800 10.1001/jama.2016.0291 26903337 · DOI · Paper page
  77. [81]Umbrello M Formenti P Bolgiaghi LU Chiumello D Current concepts of ARDS: a narrative review Int J Mol Sci 2017 18 64 10.3390/ijms18010064 PMC5297699 28036088 · DOI
  78. [82]Martin TR Lung cytokines and ARDS: Roger S Mitchell lecture Chest 1999 116 1 Suppl 2S 8S 10.1378/chest.116.suppl_1.2S 10424558 · DOI
  79. [84]Lees NJ Rosenberg A Hurtado-Doce AI Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leucocidin-positive Staphylococcus aureus pneumonia and H1N1 J Artif Organs 2016 19 4 399 402 10.1007/s10047-016-0915-8 27436098 · DOI
  80. [85]Traeger K, Schuetz C, Fischer G, et al. Cytokine reduction in the setting of an ARDS-associated inflammatory response with multiple organ failure. In: Case reports in critical care. PMC4739007 26885411
  81. [86]Bruenger F Kizner L Weile J Morshuis M Gummert JF First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report Int J Artif Organs 2015 30 113 116 10.5301/ijao.5000382 25656010 · DOI
  82. [87]Becze Z Molnar Z Fazakas J Can procalcitonin levels indicate the need for adjunctive therapy in sepsis? Int J Antimicrob Agents 2015 46 Suppl 1 S13 S18 10.1016/j.ijantimicag.2015.11.002 26621136 · DOI
  83. [88]Pupelis G Drozdova N Mukans M Malbrain ML Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis Inflammation 2014 37 1 223 234 10.1007/s10753-013-9733-9 25293477 · DOI
  84. [89]Trásy D Tánczos K Németh M EProK study group Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: a prospective observational study J Crit Care 2016 34 50 55 10.1016/j.jcrc.2016.04.007 27288610 · DOI
  85. [90]Vincent JL de Mendonça A Cantraine F Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine Crit Care Med 1998 26 1793 1800 10.1097/00003246-199811000-00016 9824069 · DOI · Paper page
  86. [91]Poli Elettra Camille Simoni Chiara André Pascal Buclin Thierry Longchamp David Perez Marie-Hélène Ferry Thomas Schneider Antoine Guillaume Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study The International Journal of Artificial Organs 2019 42 5 258 262 10.1177/0391398819831303 30819024 · DOI

Cited by

Sorted by citations

Authors
Honore, P. M., Hoste, E., Molnár, Z., Jacobs, R., Joannes-Boyau, O., Malbrain, M. L. N. G., & Forni, L. G.
Affiliations
  • Ghent University Hospital (BE)
  • University of Szeged (HU)
  • Universitair Ziekenhuis Brussel (BE)
  • Vrije Universiteit Brussel (BE)
  • Royal Surrey County Hospital (GB)
ORCID
Venue
Annals of Intensive Care
Publisher
Elsevier BV
Published
2019
Volume
9
Issue
1
Pages
56
ISSN
2110-5820 (ISSN-L)
DOI
10.1186/s13613-019-0530-y
PMC
PMC6517449
OpenAlex
W2945686759
Cited by
192
References
4
Citations by year
2026: 17 · 2025: 16 · 2024: 23 · 2023: 28 · 2022: 26 · 2021: 31 · 2020: 44 · 2019: 6 · 2015: 1
FWCI
3.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Intensive Care (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • CytoSorbents Europe
  • International Fund for Agricultural Development
Topics
  • Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
septic shock, cytokine removal, blood purification, endotoxin removal, inflammatory mediators, immune homeostasis, sepsis treatment, Delphi consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review